Evaluation of a DTPA Prodrug, C2E5 as an Orally Bioavailable Radionuclide Decorporation Agent

Evaluation of a DTPA Prodrug, C2E5 as an Orally Bioavailable Radionuclide Decorporation Agent

Strategy, Management and Health Policy Enabling Technology, Genomics, Proteomics Preclinical Research Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics Clinical Development Phases I‐III Regulatory, Quality, Manufacturing Postmarketing Phase IV The efficacy of the prodru...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug development research 2012-08, Vol.73 (5), p.243-251
Hauptverfasser: Sadgrove, Matthew P., Leed, Marina G. D., Shapariya, Shraddha, Madhura, Dora Babu, Jay, Michael
Format: Artikel
Sprache:eng
Schlagworte:
americium
decorporation
DTPA
oral drug delivery
prodrug
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Strategy, Management and Health Policy Enabling Technology, Genomics, Proteomics Preclinical Research Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics Clinical Development Phases I‐III Regulatory, Quality, Manufacturing Postmarketing Phase IV The efficacy of the prodrug C2E5, the pentaethyl ester of diethylenetriaminepentaacetic acid (DTPA), as an orally administered chelator of americium was evaluated in rats. C2E5 enhanced 241Am decorporation over vehicle‐only controls (187 μmol/kg, 14.8 ± 4.2% vs control, 7.1 ± 1.4% injected 241Am, P 
ISSN:0272-4391
1098-2299
DOI:10.1002/ddr.21019